EХPERIENCE IN INTERFERON β-1A USE FOR TREATMENT OF MULTIPLE SCLEROSIS IN CHILDREN
نویسندگان
چکیده
منابع مشابه
Interferon β-1a and Atorvastatin in the Treatment of Multiple Sclerosis
Background: Statins, widely used cholesterol-lowering agents, have also been demonstrated to have anti-inflammatory and immunomdulatory effects. Objective: To evaluate the effects of atorvastatin in combination with Interferon-β in the treatment of multiple sclerosis (MS) in a randomized controlled clinical trial. Methods: Multiple sclerosis patients were randomized independently, in a double b...
متن کاملinterferon β-1a and atorvastatin in the treatment of multiple sclerosis
background: statins, widely used cholesterol-lowering agents, have also been demonstrated to have anti-inflammatory and immunomdulatory effects. objective: to evaluate the effects of atorvastatin in combination with interferon-β in the treatment of multiple sclerosis (ms) in a randomized controlled clinical trial. methods: multiple sclerosis patients were randomized independently, in a double b...
متن کاملReview of the clinical evidence for interferon β 1a (Rebif®) in the treatment of multiple sclerosis
Interferon (INF) beta 1a 22 or 44 mug (Rebif((R))) administered s.c. 3 times a week (t.i.w) is a well established immunomodulating treatment for relapsing remitting multiple sclerosis (RRMS). This review focuses on its mechanisms of action, evidence of efficacy, safety, and tolerability. Several pharmacodynamic properties explain the immunomodulatory actions of INF beta 1a 22 or 44 mug s.c. t.i...
متن کاملInterferon β-1a and Atorvastatin in the Treatment of Multiple Sclerosis.
BACKGROUND Statins, widely used cholesterol-lowering agents, have also been demonstrated to have anti-inflammatory and immunomdulatory effects. OBJECTIVE To evaluate the effects of atorvastatin in combination with Interferon-β in the treatment of multiple sclerosis (MS) in a randomized controlled clinical trial. METHODS Multiple sclerosis patients were randomized independently, in a double ...
متن کاملDelayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis
Interferon β-1a is a widely used immunomodulation treatment for multiple sclerosis. Liver function impairment is a common side effect and usually develops in the first 6 months after interferon use. Here, we describe 2 multiple sclerosis patients who developed delayed liver function impairment 5 years after receiving interferon β-1a treatment. Their liver function recovered after discontinuing ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current pediatrics
سال: 2013
ISSN: 1682-5535
DOI: 10.15690/vsp.v12i5.794